European Times European Times Big Sampling
European epidemic data on April 12
French News added 8536 cases, a total of 5107943 confirmed cases, a total of 385 deaths, a total of 99135 deaths;
Spain 6News added 22744 cases, a total of 3370256 confirmed cases, a total of 197 deaths, a total of 76525 deaths;
UK has 3568 new cases, with a total of 4373343 confirmed cases, with a total of 13 new deaths and a total of 127,100 deaths;
Italian has 9789 new cases, with a total of 3779,594 new cases, with a total of 358 new deaths and a total of 114,612 deaths;
Germany on the 11th, with a total of 17,803 new cases, with a total of 3007,373 new cases, with a total of 95 new deaths and a total of 78,425 deaths.
On April 12, France started to fight for the new crown vaccine (hereinafter referred to as the Johnson & Johnson vaccine) developed by Janssen Pharmaceutical Co., Ltd., a subsidiary of the American Johnson & Johnson company. However, just as the Johnson & Johnson vaccine has not been given a large scale in Europe, the European Medicines Agency (EMA) announced on April 9 that in view of the four cases of Johnson & Johnson vaccine thrombosis in the United States, the DRU has launched an investigation into the vaccine to verify whether it is related to thrombosis in . At the same time, some French medical insiders pointed out that AstraZeneca /Oxford vaccinated patients had blood clots, or because the vaccine was "incorrectly shot" - the intramuscular injection was not performed as required, but was incorrectly injected into the blood vessel.
French "Mr. Vaccines": 90% of the people have difficulty getting vaccinated against the new crown vaccine
"Mr. Vaccines" appointed by the French government and immunologist Fischer (Alain Fischer) said on April 12 that it is "very difficult" to achieve vaccination of 90% of the people. According to a research model of the Pasteur Institute in France, if 90% of the people can be vaccinated in September this year, life is expected to return to normal.
Fisher pointed out that at present, the youngest group does not fully believe in vaccines, "For themselves and their relatives, we must convince them."
Fisher also pointed out that the French people's concept of vaccination is different from that of the United States and the United Kingdom. For example, when it comes to vaccinating children with influenza vaccines, the United States and the United Kingdom vaccinate children in large quantities in order to prevent children from spreading the virus to the elderly; but the French do not think so. "In terms of the new crown vaccine, we must move closer to this direction (UK and the United States)," Fisher admitted.
.2 million doses of Johnson & Johnson vaccine arrived one week in advance
Starting today (12th), people aged 55 and over in France can receive the AstraZeneca vaccine or the newly arrived Johnson & Johnson vaccine.
▲ Johnson & Johnson vaccine was approved by the European Medicines Agency (EMA) on March 11, becoming the fourth vaccine to be licensed by the EU after the Pfizer/BioNTech, Moderna and AstraZeneca/Oxford vaccines. (Photo by AFP)
is different from the AstraZeneca vaccine that has repeatedly delayed delivery. 200,000 doses of the US Johnson & Johnson COVID-19 vaccine arrived in France "a week ahead of schedule", which made French Health Minister Wei Lang unable to help but glad in the interview on Sunday Weekly that "vaccination (range) can be expanded."
Franceinfo news website pointed out that Johnson & Johnson has cooperated with several European pharmaceutical factories, including France's Sanofi, so there is no need to worry about production issues. The most critical active ingredient (antigen) of Johnson & Johnson's vaccine comes from Johnson & Johnson's factory in Leiden, Netherlands.
can reduce severe 85%
AFP reported that the trial of Johnson & Johnson vaccine in the United States, Mexico , Brazil and South Africa in countries such as South Africa for 40,000 people (over 18 years old) shows that the vaccine can reduce severe COVID-19 (i.e., reduce hospitalizations and deaths). No one in the vaccine group participating in the trial died of the new coronavirus, while seven people in the placebo group were infected with the new coronavirus.
According to the U.S. Food and Drug Administration (FDA), the Johnson & Johnson vaccine can reduce moderate to severe symptoms by 66%: this proportion reaches 72% in the United States, and about 64% in South Africa where the mutant virus is prevalent.
▲ Although the trial data previously released by Pfizer/BioNTech and Moderna's new crown vaccines showed that the best protection is as high as 95%, experts pointed out that in the clinical trials of the above two vaccines, the mutant virus (especially South African mutation) has not yet become the dominant strain in the trial countries. The picture shows the Pfizer vaccine. (AFP photo)
single injection adenovirus vector vaccine:
safe and cheap, but the effect on mutant viruses may be limited
is the same as Asley Cam/Oxford vaccine. Johnson & Johnson vaccine also uses adenovirus vector technology. The working principle is as follows:
uses modified harmless adenovirus as a vector, loads the S protein gene of the new coronavirus to make an adenovirus vector vaccine, and stimulates the human body to produce antibodies. The advantages are safety, efficiency and few adverse reactions.
▲ S protein is the key "key" for the new coronavirus to invade human cells. The harmless adenovirus wears the "hat" of S protein and pretends to be "hard" to make people feel immune to the body. China Tianjin CanSino is adenovirus vector vaccine produced by China's Tianjin.
In addition, Johnson & Johnson vaccines can be stored in ordinary refrigerators for three months, making cold chain transportation more convenient, which provides greater flexibility for pharmacies and vaccination centers. What is "better" than the AstraZeneca vaccine is that the Johnson & Johnson vaccine is a single shot vaccine, and you only need one dose to get protection against the new coronavirus. Single-dose vaccines are relatively low in cost. In the current global vaccine production capacity, single-dose vaccines can be vaccinated with double the population, improving the accessibility of the vaccine.
But experts also pointed out that the intensity of the immune response induced by a single-dose adenovirus vector vaccine is generally weaker than that of two-dose vaccines. Therefore, this type of single-dose vaccine is fine when preventing early epidemic viruses, but when facing mutant viruses, the protection efficiency will mostly decrease.
▲ The "Vaccine Mr." appointed by the French government, an immunologist Alain Fischer, said in an interview with the Liberation Daily that he had some "doubt" about the protection of the Johnson & Johnson vaccine: "I don't know why other vaccines cannot do it, only it (JP Johnson & Johnson vaccine) can do it. Let's wait and see if the vaccinator can really be exempted from receiving the second shot." (AFP photo) Is
related to thrombosis?
AFP reported that after four Johnson & Johnson vaccinators in the United States developed blood clots, the European Medicines Agency (EMA) announced on April 9 that it had launched an investigation into the Johnson & Johnson COVID-19 vaccine to verify whether it is related to thrombosis.
Four Johnson & Johnson vaccinated patients in the United States developed severe thrombosis and hypoplatelets (similar to the AstraZeneca vaccine thrombosis). Three of them developed thrombosis after mass vaccination of this vaccine, and one died of coagulation disorders during the clinical trial stage. The U.S. Food and Drug Administration said in a statement on the 9th: "We have not found a causal relationship between (thrombosis) and vaccination (JP Johnson & Johnson vaccine), and will continue to investigate and evaluate those cases. Data analysis will guide possible (implemented) regulatory behavior."
thrombosis or is it because the vaccine is in the wrong position?
Although the European Medicines Agency has admitted that thrombosis is a "rare" adverse reaction to AstraZeneca vaccine, the medical community is not clear why vaccinated people with no particular health problems will develop this atypical thrombosis after getting vaccinated.
Le Figaro previously reported that Professor Andreas Greinacher's research team at the University of Greifswald in Germany believes that this may be related to the autoimmune response: for unknown reasons, some people will produce antiplatelet antibodies after vaccination, which on the one hand will lead to platelet aggregation; on the other hand, these antibodies bind to platelets, causing sensitized platelets to be phagocytically destroyed in the monocyte macrophage system, resulting in thrombocytosis. This explains why patients experience venous thrombosis and thrombocytopenia at the same time. This is very similar to heparin-induced thrombocytopenia (HIT) with thrombosis.
In addition to this explanation by Professor Andreas Greinacher in Germany, some French researchers recently pointed out that the formation of a thrombus may be the wrong position of the vaccine!
French tumor immunology expert Éric Billy and pulmonary expert Corinne Depagne recently pointed out that the new crown vaccine is intramuscular injection. A thrombosis occurs after vaccination or because the vaccine is not injected into the muscle tissue, but is an adverse reaction caused by mistake injecting into the blood vessels!
Experts from "West France" pointed out that once the S protein recombinant adenovirus in the vaccine is mistakenly injected into the blood vessels, it will quickly enter the blood circulation, causing the human body to have an "overly violent immune response and increase the risk of thrombosis". Therefore, it can be said that this is a "specific" adverse reaction to the adenovirus vector vaccine. and Pfizer and Moderna vaccines inject mRNA into the human body, using human cells to synthesize S proteins in the human body, stimulating the human body to produce antibodies, so there will be no such risk.
▲Please take care of the vaccine to see if the nurse has checked for recovery... (AFP Photo)
Experts stressed that in order to avoid injecting the vaccine into the blood vessel, medical staff check for recovery before injection of the medicine: After injection of the injection of the injection of the medicine, the syringe piston must be ticked to check for recovery of recovery. If there is a recovery of blood in the intramuscular injection of vaccines, it means that the blood vessel has been stabbed. At this time, the needle must be pulled out and the injection of the medicine again. Do not inject the medicine into the blood vessel, otherwise it may cause changes in the medication method, and may even cause adverse drug reactions or drug poisoning in the vaccinator.
(European Times/Yellow Report)
